This trial is active, not recruiting.

Condition epilepsy
Sponsor Yi Yang
Start date April 2016
End date May 2017
Trial size 100 participants
Trial identifier NCT02775682, CA&EEG


The purpose of this study is to determine whether patients with epilepsy exhibiting impaired dCA, which may contribute to subsequent stroke.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Primary Outcomes

phase difference(PD) in degree
time frame: 1 year

Secondary Outcomes

the rate of recovery of cerebral blood flow velocity
time frame: 1 year
gain in cm/s/mmHg
time frame: 1 year
the consequence of electroencephalograph(EEG)
time frame: 1 year

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria

  • patients with epilepsy, as diagnosed by EEG

Exclusion Criteria

  • middle cerebral artery (MCA) and/or other intracranial and/or extracranial major vascular stenosis/occlusion, as diagnosed by a transcranial Doppler
  • having a prior symptomatic cerebrovascular disease
  • having a history of hypertension, diabetes, or hyperlipemia
  • current arrhythmia, hyperthyroidism, anemia and unstable blood pressure, which may undermine hemodynamic stability
  • inability to cooperate sufficiently to complete the dCA examination

Additional Information

Official title Cerebral Autoregulation in Patients With Epilepsy
Description The relationship between epileptic seizures and cerebrovascular disease is complex, ranging from mechanisms to clinical manifestation. Stroke is one of the most common causes of epilepsy in adulthood. It was also reported that patients with epilepsy exhibited a higher risk of stroke. But its potential mechanism was never fully understood. Dynamic cerebral autoregulation(dCA), a mechanism to maintain the cerebral bold flow, has been proved to be critical for the occurrence ,development and prognosis of ischemic neurovascular disease. In this study, we hypothesis that impaired dCA play a role in epilepsy and subsequent stroke.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by First Hospital of Jilin University.